<sup>177</sup> Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer

20250 citationsJournal Article

Authors

Boris Hadaschik · Essen University Hospital

Silke Gillessen · Università della Svizzera italiana

Oliver Sartor · East Jefferson General Hospital

Abstract

Giri et al. present a case report involving a patient with metachronous low-volume metastatic hormone-sensitive prostate cancer (mHSPC) who declined standard treatments such as androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPI), and taxane chemotherapy because of

Topics & Keywords

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Cancer, Lipids, and Metabolism

Publication Details

Published in: Journal of Nuclear Medicine

Volume 66, Issue 11, pp. 1688-1689

DOI: 10.2967/jnumed.125.270836

Field-Weighted Citation Impact: 0.00

Command Palette

<sup>177</sup> Lu-PSMA-617 Monotherapy Is Provocative but No Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer

Authors

Abstract

Topics & Keywords

Publication Details